Is intravenous immunoglobulin (Immunosin) appropriate for treating measles infection?

Immunosin (IVIG) for Measles: Not for Treatment, Only for Post-Exposure Prevention

Intravenous immunoglobulin (IVIG) like Immunosin is NOT appropriate for treating active measles infection—it is only indicated for post-exposure prophylaxis in specific high-risk individuals within 6 days of exposure.

Critical Distinction: Prevention vs. Treatment

The evidence is clear that immunoglobulin has no role in treating established measles infection. Its sole purpose is preventing or modifying measles in susceptible individuals after known exposure but before symptom onset 1.

When IVIG Is Appropriate (Post-Exposure Prophylaxis Only)

IVIG should be administered within 6 days of measles exposure to the following high-risk groups 1:

Priority Groups for IVIG Prophylaxis:

• Infants <6 months of age (though those <6 months usually have maternal antibodies)
• Pregnant women without evidence of immunity
• Severely immunocompromised patients (including symptomatic HIV-infected patients), regardless of vaccination status 1
• Infants 6-12 months who are household contacts and cannot receive vaccine within 72 hours 1

Dosing for Post-Exposure Prophylaxis:

• Standard dose: 0.25 mL/kg IM (maximum 15 mL) 1
• Immunocompromised patients: 0.5 mL/kg IM (maximum 15 mL) 1
• IVIG (intravenous): 100-400 mg/kg IV 1
• Recent evidence supports: 400 mg/kg IV as single dose 2, 3

Why Vaccine Is Preferred Over Immunoglobulin

For most exposed individuals ≥12 months old, MMR vaccine given within 72 hours is preferable to immunoglobulin 1. The vaccine provides:

• Active, long-lasting immunity
• Some protection even if exposure results in infection
• No interference with future vaccination

Common Pitfalls to Avoid

1. Do NOT use immunoglobulin to treat active measles - it has no therapeutic benefit once symptoms begin
2. Do NOT use IG to control measles outbreaks 1 - vaccination is the appropriate intervention
3. Timing is critical - IG must be given within 6 days of exposure; effectiveness decreases with delay 1
4. Remember vaccine interference - if IG is given, subsequent MMR vaccination must be delayed 5-6 months 1

Important Caveats About Current IVIG Products

Recent research highlights a critical concern: measles antibody concentrations in donor-derived immunoglobulin products have declined as vaccinated (rather than naturally immune) donors comprise more of the plasma pool 2, 3. However:

• A 2021 Austrian study demonstrated 99.3% effectiveness of 400 mg/kg IVIG in preventing measles in exposed infants 3
• A 2025 study confirmed protective measles antibody levels (~1300 mIU/mL) well above accepted thresholds in current IVIG products 4
• German guidelines now recommend 400 mg/kg IV (rather than lower IM doses) to ensure adequate antibody delivery 2

What About the "Immunosin" Product Mentioned?

The FDA drug labels provided 5 describe "Aminosyn II"—an amino acid solution for parenteral nutrition, NOT an immunoglobulin product. This appears to be a confusion in product naming. If you're asking about an actual immunoglobulin product for measles prophylaxis, you need a true IVIG preparation (such as Gammaplex, IgVena, or similar products containing measles-specific antibodies).

Bottom Line Algorithm

For measles exposure in susceptible individuals:

1. Within 72 hours → Give MMR vaccine (if ≥12 months, not pregnant, not immunocompromised)
2. 72 hours to 6 days OR high-risk groups → Give IVIG 400 mg/kg IV
3. After 6 days → Prophylaxis ineffective; monitor for symptoms
4. Active measles infection → Supportive care only; immunoglobulin has no role